Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (August 2009). "Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers". Clinical Therapeutics. 31 (8): 1652–1663. doi:10.1016/j.clinthera.2009.08.010. PMID19808126. S2CID42580226.
Klotz U (2002). "Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist". Arzneimittel-Forschung. 52 (3): 155–161. doi:10.1055/s-0031-1299873. PMID11963641. S2CID38892707.
Chen K, Zhang J, Liu S, Zhang D, Teng Y, Wei C, et al. (June 2012). "Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 899: 1–7. doi:10.1016/j.jchromb.2012.04.014. PMID22622066.
espacenet.com
worldwide.espacenet.com
US 6852737, Bonifacio F, Campana F, De Iasi G, Leonardi A, "Crude and crystalline forms of lercanidipine hydrochloride", issued 8 February 2005, assigned to Recordati Ireland Ltd.
Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (August 2009). "Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers". Clinical Therapeutics. 31 (8): 1652–1663. doi:10.1016/j.clinthera.2009.08.010. PMID19808126. S2CID42580226.
Klotz U (2002). "Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist". Arzneimittel-Forschung. 52 (3): 155–161. doi:10.1055/s-0031-1299873. PMID11963641. S2CID38892707.
Chen K, Zhang J, Liu S, Zhang D, Teng Y, Wei C, et al. (June 2012). "Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 899: 1–7. doi:10.1016/j.jchromb.2012.04.014. PMID22622066.
Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (August 2009). "Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers". Clinical Therapeutics. 31 (8): 1652–1663. doi:10.1016/j.clinthera.2009.08.010. PMID19808126. S2CID42580226.
Klotz U (2002). "Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist". Arzneimittel-Forschung. 52 (3): 155–161. doi:10.1055/s-0031-1299873. PMID11963641. S2CID38892707.